ETILX - Eventide Gilead I

Nasdaq - Nasdaq Delayed Price. Currency in USD
36.19
+0.66 (+1.86%)
At close: 8:00PM EST
Stock chart is not supported by your current browser
Previous Close35.53
YTD Return33.09%
Expense Ratio (net)1.20%
CategoryMid-Cap Growth
Morningstar Rating★★★★☆
Morningstar Risk RatingHigh
Last Cap Gain0.00
Net Assets1.58B
Beta (3y)1.31
Yield0.00%
Holdings Turnover26.00%
Last Dividend0.00
Inception DateFeb 2, 2010
Average for CategoryN/A
  • PR Newswire26 days ago

    Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund Named WSJ Category Kings for 2017

    BOSTON, Jan. 30, 2018 /PRNewswire/ -- The Eventide Gilead Fund (ETILX) and the Eventide Healthcare & Life Sciences Fund (ETIHX) were both named as "Category Kings" by the Wall Street Journal for 2017. Both Funds are managed by Eventide Asset Management, LLC, a Boston-based registered investment adviser that designs investments for performance and a better world. Eventide CEO Robin John commented, "We are pleased with the results, yet more importantly, proud of how they were achieved.

  • PR Newswire7 months ago

    Eventide Gilead Fund Named a WSJ Category King

    BOSTON, July 31, 2017 /PRNewswire/ -- The Eventide Gilead Fund (NASDAQ: ETGLX, NASDAQ: ETAGX, NASDAQ: ETCGX, NASDAQ: ETILX) received a Wall Street Journal "Category King" on June 30, 2017. The award recognizes the top 10 funds in each equity category for one-year total return performance.

  • We're sorry this is all we were able to find about this topic.